クリングルファーマ㈱
2 known investors
Kringle Pharma is a late-stage regenerative-medicine biotech developing therapies based on the HGF (hepatocyte growth factor) protein, which protects and repairs tissues and organs. The company runs clinical trials targeting rare and intractable diseases and has established pharmaceutical-grade HGF protein manufacturing as its platform.
Investors · 2
Frequently asked questions
- What does クリングルファーマ㈱ do?
- Kringle Pharma is a late-stage regenerative-medicine biotech developing therapies based on the HGF (hepatocyte growth factor) protein, which protects and repairs tissues and organs. The company runs clinical trials targeting rare and intractable diseases and has established pharmaceutical-grade HGF protein manufacturing as its platform.
- Who are クリングルファーマ㈱'s investors?
- クリングルファーマ㈱'s investors include DBJ Capital, OSAKA University Venture Capital.